Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer

Biomolecules(2025)10.3390/biom15070948Source: DataRank Database

PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer is a research paper published in Biomolecules (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.39)OA: goldTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

William J. Kane ORCID,Sara J. Adair ORCID,Sarbajeet Nagdas,Denis Liu,Todd W. Bauer ORCID

Live enrichment

PubMed:40723820 PMC:PMC12292163 OpenAlex:https://openalex.org/W4411929675

Farrell Family Foundation Fund

Grant: PJ03176

Farrell Family Foundation Fund

Grant: T32CA163177

Farrell Family Foundation Fund

Grant: P30CA044579

NIH HHS

Grant: 5T32MD163177-21

National Institutes of Health

Grant: 3P30CA044579-19S1

Cancer Center Support Grant

National Institutes of Health

Grant: 5T32CA163177-03

Postdoctoral Training Grant for MDs in Surgical Oncology Research

FWCI

0.39

Citation Percentile

0.6%

Citation Trend

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2218-273X/15/7/948/pdf?version=1751273039

GOLDhttps://www.mdpi.com/2218-273X/15/7/948/pdf?version=1751273039

publisherhttps://www.mdpi.com/2218-273X/15/7/948/pdf?version=1751273039

publisherhttps://www.mdpi.com/2218-273X/15/7/948/pdf

journalhttps://doi.org/10.3390/biom15070948

Fields of Study

Cancer-related gene regulationRenal and related cancersEpigenetics and DNA MethylationMedicine03 medical and health sciences0302 clinical medicine

MeSH Terms

GemcitabineAnimalsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDisease Models, AnimalFemaleHumansPancreatic NeoplasmsProtein-Arginine N-MethyltransferasesPaclitaxelMice, KnockoutCarcinoma, Pancreatic DuctalXenograft Model Antitumor AssaysCell Line, TumorMice

Keywords

Protein arginine methyltransferase 5MedicineGemcitabinePancreatic cancerFOLFIRINOXCancerCancer researchPaclitaxelCombination therapyOncologyInternal medicinePharmacologyIrinotecanMethyltransferaseBiologyColorectal cancerDNA damagetherapeutic targetPrmt5Orthotopic Pdx Mouse ModelProtein-Arginine N-MethyltransferasesMicrobiologyDeoxycytidineArticleMiceCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansMice, KnockoutXenograft Model Antitumor AssaysQR1-502Pancreatic NeoplasmsDisease Models, AnimalFemaleCarcinoma, Pancreatic Ductal

Sustainable Development Goals

SDG 0: Good health and well-being

PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer

FAIR Checklist

Authors (6)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)